Year All2024202320222021202020192018201720162015 Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting December 9, 2024 Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc. November 26, 2024 Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline November 14, 2024 Poseida Therapeutics to Present at Two Upcoming Investor Conferences November 11, 2024 Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024 November 7, 2024 Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024 November 5, 2024 Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema October 24, 2024 Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche October 17, 2024 Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 October 3, 2024 Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients September 27, 2024
Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting December 9, 2024
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc. November 26, 2024
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline November 14, 2024
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024 November 7, 2024
Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024 November 5, 2024
Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema October 24, 2024
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche October 17, 2024
Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 October 3, 2024
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients September 27, 2024
